Literature DB >> 23065524

The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.

Daan Dierickx1, Thomas Tousseyn, Annelies Requilé, Raf Verscuren, Xavier Sagaert, Julie Morscio, Iwona Wlodarska, An Herreman, Dirk Kuypers, Johan Van Cleemput, Frederik Nevens, Lieven Dupont, Anne Uyttebroeck, Jacques Pirenne, Christiane De Wolf-Peeters, Gregor Verhoef, Lieselot Brepoels, Olivier Gheysens.   

Abstract

We investigated sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-fluorodeoxyglucose-positron emission tomography in 170 cases with suspected or biopsy-proven posttransplant lymphoproliferative disorder. All solid organ and hematopoietic stem cell transplant recipients who underwent an 18F-fluorodeoxyglucose-positron emission tomography scan between 2003 and 2010 in our center for the indication posttransplant lymphoproliferative disorder, were retrospectively reviewed and results were compared with tissue biopsy whenever possible. One hundred and seventy positron emission tomography scans in 150 patients were eligible for evaluation. In 45 cases, the patient had a biopsy-confirmed posttransplant lymphoproliferative disorder before positron emission tomography scanning and positron emission tomography was performed for staging purposes. In the remaining 125 cases, positron emission tomography was performed to differentiate between posttransplant lymphoproliferative disorder and other diseases. 18F-fluorodeoxyglucose-uptake was quantitatively expressed by calculation of maximum and mean standardized uptake value in the most intense lesion or, in the absence of attenuation corrected positron emission tomography scans, by comparing uptake in target lesion to liver and mediastinal uptake. We found an overall sensitivity of 89%, specificity of 89%, positive predictive value of 91% and negative predictive value of 87% for posttransplant lymphoproliferative disorder detection by 18F-fluorodeoxyglucose-positron emission tomography. In a subanalysis of the 125 scans performed for differentiating posttransplant lymphoproliferative disorder from other diseases, sensitivity, specificity, positive predictive value and negative predictive value were 90%, 89%, 85% and 93%, respectively. 18F-fluorodeoxyglucose-uptake in posttransplant lymphoproliferative disorder was generally high with a median mean and maximum standardized uptake value of 9.0 (range 2.0-18.6) and 17.4 (range 2.6-26.4). Posttransplant lymphoproliferative disorder often had an atypical presentation on positron emission tomography with high incidence of extranodal involvement. In conclusion, from these data, we can conclude that 18F-fluorodeoxyglucose-positron emission tomography is highly sensitive for detecting posttransplant lymphoproliferative disorder and has an excellent ability to differentiate posttransplant lymphoproliferative disorder from non-malignant diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065524      PMCID: PMC3640123          DOI: 10.3324/haematol.2012.074500

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  PTLD visualization by FDG-PET: improved detection of extranodal localizations.

Authors:  N A Bakker; J Pruim; W de Graaf; W J van Son; E J van der Jagt; G W van Imhoff
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

2.  Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.

Authors:  Sith Phongkitkarun; Vithya Varavithya; Toshiki Kazama; Silvana C Faria; Martha V Mar; Donald A Podoloff; Homer A Macapinlac
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 3.  Malignancy after transplantation.

Authors:  Joseph F Buell; Thomas G Gross; E Steve Woodle
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

4.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

Authors:  Heiko Schöder; Ariela Noy; Mithat Gönen; Lijun Weng; David Green; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

5.  Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.

Authors:  M Lapela; S Leskinen; H R Minn; P Lindholm; P J Klemi; K O Söderström; J Bergman; M Haaparanta; U Ruotsalainen; O Solin; H Joensuu
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

6.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

Authors:  G Jerusalem; Y Beguin; F Najjar; R Hustinx; M F Fassotte; P Rigo; G Fillet
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

7.  FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation.

Authors:  Angus R O'Conner; Benjamin L Franc
Journal:  Nucl Med Commun       Date:  2005-12       Impact factor: 1.690

8.  Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients.

Authors:  Edith M Marom; H Page McAdams; Kelly J Butnor; R Edward Coleman
Journal:  J Thorac Imaging       Date:  2004-04       Impact factor: 3.000

Review 9.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma.

Authors:  M Rodriguez; S Rehn; H Ahlström; C Sundström; B Glimelius
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  11 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation.

Authors:  Nastassja Muller; Romain Kessler; Sophie Caillard; Eric Epailly; Fabrice Hubelé; Céline Heimburger; Izzie-Jacques Namer; Raoul Herbrecht; Cyrille Blondet; Alessio Imperiale
Journal:  Nucl Med Mol Imaging       Date:  2016-11-28

Review 3.  Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

Authors:  Daan Dierickx; Nina Cardinaels
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 4.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

Review 5.  FDG-PET/CT in abdominal post-transplant lymphoproliferative disease.

Authors:  Ur Metser; Glen Lo
Journal:  Br J Radiol       Date:  2015-11-06       Impact factor: 3.039

6.  Postrenal Transplant Metastatic Colonic Neoplasm: Posttransplant Lymphoproliferative Disorder or Adenocarcinoma?

Authors:  H Lal; P Yadav; M Dey; N Kumar
Journal:  Indian J Nephrol       Date:  2017 May-Jun

Review 7.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.

Authors:  Ayumi Fujimoto; Ritsuro Suzuki
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

8.  Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.

Authors:  F M Montes de Jesus; T C Kwee; X U Kahle; M Nijland; T van Meerten; G Huls; R A J O Dierckx; S Rosati; A Diepstra; W van der Bij; E A M Verschuuren; A W J M Glaudemans; W Noordzij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-24       Impact factor: 9.236

9.  Lymphoproliferative disorder in a lung transplant recipient.

Authors:  Hassan A Haji; Douglas S Corwin; Jennifer Y So; Robert M Reed
Journal:  BMJ Case Rep       Date:  2020-03-31

10.  Late Posttransplant Lymphoproliferative Disease: Report of a Rare Case and Role of Positron Emission Tomography-computed Tomography.

Authors:  P Yadav; N Kumar; N Prasad; H Lal
Journal:  Indian J Nephrol       Date:  2018 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.